What Spindle Biotech does

Spindle Biotech (operating as "스핀들 / Spindle") is a private, South Korea-based direct-to-consumer health company commercializing a single Akkermansia muciniphila-based dietary supplement positioned around the "gut-muscle axis." The company targets health-conscious adults in their 30s–50s who are concerned with age-related metabolic decline, sarcopenia, and muscle recovery, and frames its offering around the role of Akkermansia in promoting mucin production, gut-barrier integrity, and reduced chronic inflammation — supported by cited academic literature and an R&D advisory relationship with Professor Marcia C. Haigis of Harvard Medical School, a specialist in mitochondrial metabolism.

The company sells exclusively through its Korean-language e-commerce storefront (spindle.bio) under both subscription (정기구독) and one-time purchase (구매하기) options, making subscription economics the core revenue model. The product portfolio is a single SKU — the Spindle Akkermansia Supplement — and marketing is content-driven, emphasizing scientific education, customer testimonials, and reference-backed claims rather than paid acquisition or omnichannel distribution.

Operationally, the company is small (1–10 employees) and private, with no disclosed funding amounts beyond participation in SOSV and RebelBio accelerator rounds in 2019 and 2022. No revenue, headcount growth, geographic expansion, or institutional ownership information is available. The input data also contains a separately referenced entity ("Spindle Bio, Inc.") acquired by LineaRx/BNB Plus Corp. in July 2023 for RNA polymerase technology — per the source commentary, this is a distinct biopharmaceutical company unrelated to the consumer health company at spindle.bio; investors should treat that transaction as out-of-scope for the entity described here.

Name

Spindle Biotech

Legal name

Spindle Biotech (legal name not explicitly stated on website)

Website

https://spindle.bio

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

mRNA Production Biotech Tools

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC) (HLAAADAF)

akta.pro secondary industries

mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)

Keywords

• MRNA production
• RNA polymerase
• Vaccine manufacturing
• Biotech enzymes
• In vitro transcription

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

1. Direct-to-Consumer Supplement Sales: Spindle generates revenue through direct sales of Akkermansia-based health supplements to consumers via their e-commerce platform. The company offers subscription options for regular product deliveries, indicating a recurring revenue model.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Spindle Biotech is commercializing a proprietary, chemically modified RNA polymerase (RNAP) enzyme branded Linea RNAP for large-scale mRNA vaccine production via in vitro transcription (IVT). The enzyme technology is protected by a granted European patent validated through at least 2040 and was acquired by LineaRx (BNB Plus Corp.'s biopharmaceutical subsidiary) in July 2023 to anchor the Linea IVT platform.

Product overview

Spindle Biotech offers a single core product line centered on Akkermansia muciniphila, a next-generation microbiome ingredient. The flagship offering is an Akkermansia-based dietary supplement sold via subscription (정기구독) and one-time purchase (구매하기) through the company's e-commerce platform. The product targets gut-muscle axis health, positioning Akkermansia as the key to restoring metabolic energy and combating age-related muscle decline (sarcopenia). The company provides scientific education on the microbiome-gut-muscle connection as a complementary service to its product portfolio.

Differentiator

Problem solved

Functional benefit

Products and services

• Linea RNAP (Chemically Modified RNA Polymerase Enzyme) A proprietary, chemically modified RNA polymerase (RNAP) enzyme used as the catalytic core for in vitro transcription (IVT) in large-scale mRNA vaccine and therapeutics manufacturing. The enzyme is intended for biopharmaceutical companies producing mRNA-based products at commercial scale and underpins the Linea IVT platform.

Segments1 record

Ideal customer profiles1 record

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• BNB Plus Corp. / LineaRxcoreStrategic or Co-development Partner · 1 July 2023BNB Plus Corp.'s biopharmaceutical subsidiary LineaRx acquired Spindle Bio, Inc. in July 2023, gaining the underlying technology for their Linea IVT platform. The acquisition included intellectual property rights that led to European patent protection for the modified RNA polymerase enzyme technology.
• Harvard Medical School (Dr. Marcia C. Haigis)coreStrategic or Co-development PartnerProfessor Marcia C. Haigis from Harvard Medical School serves as Spindle's R&D Advisor. She is a renowned expert in mitochondrial metabolism and cell biology, providing scientific guidance for the company's microbiome-based metabolic health products.

Recent moves5 records

Expansion highlights3 records

Broad incumbents

• CureVac: mRNA therapeutics company with proprietary RNA technology platform including process and formulation IP. Comparable as a broader incumbent with internally developed mRNA manufacturing know-how.
• Genevant Sciences: Lipid nanoparticle and nucleic acid delivery technology company serving mRNA and siRNA developers. Comparable as a broader incumbent offering enabling technology across the RNA therapeutics manufacturing stack.
• BioNTech: Major mRNA therapeutics and vaccines company with substantial in-house manufacturing capability and process IP. Comparable as a broad incumbent whose scale and vertical integration shape the mRNA CDMO competitive landscape.
• Arcturus Therapeutics: Self-amplifying mRNA (saRNA) and conventional mRNA developer with proprietary manufacturing process IP. Comparable as a platform play with mRNA production technology underpinning multiple programs.

Emerging players

• Kernal Biologics: mRNA therapeutics company developing selective mRNA translation technology. Comparable as an emerging player with proprietary mRNA science that depends on differentiated manufacturing or process IP.
• Nutcracker Therapeutics: Developer of an integrated microfluidic mRNA manufacturing platform for personalized therapeutics. Comparable as an emerging player with proprietary mRNA production technology targeting therapeutic and vaccine customers.
• Quantoom Biosciences: Developing end-to-end, equipment-based mRNA manufacturing platforms (Ntensify and Ncapsulate). Comparable as an emerging player pushing proprietary process IP into the mRNA CDMO value chain.

Direct peers

• TriLink BioTechnologies (Maravai LifeSciences): Major mRNA CDMO and supplier of IVT reagents, CleanCap capping technology, and nucleotide raw materials. Directly comparable as a competitor supplying proprietary tools into mRNA manufacturing workflows.
• Aldevron (Danaher): Long-established CDMO for plasmid DNA, mRNA, and proteins used in cell and gene therapies and vaccines. Now part of Danaher, supplying manufacturing inputs that overlap with Spindle's enabling-technology positioning.
• LineaRx (BNB Plus Corp.): Acquirer of Spindle Bio and operator of the Linea IVT platform built around Spindle's RNA polymerase. Most directly comparable because LineaRx's commercial mRNA manufacturing offering is now built on the very technology Spindle developed.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/spindlebiotech
• LinkedInlinkedin.com/company/spindle-biotech-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spindle Biotech